Homeobox B9 Promotes the Progression of Hepatocellular Carcinoma via TGF-β1/Smad and ERK1/2 Signaling Pathways

Figure 2

Expression prolife of TGF-β1 pathway and MAPK pathway in different HOXB9 expressed HCC tissues. (A) Immunohistochemistry was performed to measure the expression of p-Smad2 in different HOXB9 expressed HCC tissues (200× magnification for the whole picture and 400× magnification for that at top right corner). (a) p-Smad2 in nontumor tissues; (b) p-Smad2 in low HOXB9 expressed HCC tissues; (c) p-Smad2 in moderate HOXB9 expressed HCC tissues; (d) p-Smad2 in high HOXB9 expressed HCC tissues; (e–f) negative control for nontumor tissues and HCC tissues, respectively. (B) Semiquantitative analysis of p-Smad2 by Immunohistochemistry in tissues from different HOXB9 expressed HCC tissues and nontumor. (C–D) Western blot was used to detect the expression of TGF-β1 signaling pathway (including Smad7, Smurf2, TGF-β1, and p-Smad2) in different HOXB9 expressed HCC tissues and nontumor. (E–F) Western blot was used to detect the expression of MAPK signaling pathway (including ERK1/2, p-38, and JNK pathway) in different HOXB9 expressed HCC tissues and nontumor. vs. nontumor.

(a)

(b)

(c)

(d)

(e)

(f)